MedPath

Cytos Biotechnology AG

πŸ‡¨πŸ‡­Switzerland
Ownership
Private, Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

36

Active:18
Completed:16

Trial Phases

2 Phases

Phase 1:6
Phase 2:12

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
12 (66.7%)
Phase 1
6 (33.3%)

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Phase 2
Withdrawn
Conditions
Asthma
First Posted Date
2014-03-14
Last Posted Date
2014-05-14
Lead Sponsor
Cytos Biotechnology AG
Registration Number
NCT02087644
Locations
πŸ‡ΊπŸ‡Έ

University of South Florida, Tampa, Florida, United States

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Phase 2
Terminated
Conditions
Moderate to Severe Allergic Asthma
First Posted Date
2012-08-28
Last Posted Date
2014-05-14
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
365
Registration Number
NCT01673672
Locations
πŸ‡ΊπŸ‡¦

Cytos Investigator Sites, Vinnytsya, Ivano-Frankivsk, Ukraine

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2009-06-18
Last Posted Date
2012-02-13
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
48
Registration Number
NCT00924105
Locations
πŸ‡¨πŸ‡­

Cytos Investigator sites, Zuerich, Switzerland

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Phase 2
Completed
Conditions
Allergic Bronchial Asthma
Interventions
Drug: Placebo
First Posted Date
2009-04-30
Last Posted Date
2012-02-13
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
63
Registration Number
NCT00890734
Locations
πŸ‡©πŸ‡ͺ

Cytos Investigator Sites, Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Phase 2
Completed
Conditions
Rhinoconjunctivitis
Allergies
Interventions
Drug: Placebo
First Posted Date
2008-12-02
Last Posted Date
2010-11-15
Lead Sponsor
Cytos Biotechnology AG
Target Recruit Count
300
Registration Number
NCT00800332
Locations
πŸ‡·πŸ‡΄

Cytos Investigator Sites, Targu Mures, Bukarest, Craiova, Iasi, Romania

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.